Collegium Pharmaceutical Inc. received Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Abuse-Deterrent Drug Formulation" US Patent Application Number 12/823,628. The Notice of Allowance is the USPTO’s official communication that the company’s application has successfully completed examination and that a patent will be issued. This will be the third issued patent related to the DETERx drug delivery technology.
The allowed patent claims cover the company’s lead development program Oxycodone DETERx (COL-003), a tamper-resistant, extended-release oxycodone product utilizing its proprietary DETERx technology. The Oxycodone DETERx formulation was specifically designed to provide and preserve extended release of the active ingredient following the most common methods of product tampering employed by drug abusers (e.g., crushing, chewing, heating for IV injection, etcetera). The product is currently in the final stage of clinical development and has been designated Fast Track Status by the FDA due to its potential to address the problem of prescription drug abuse, a major public health issue in the U.S.
“These newly allowed, product specific claims strengthen and expand our overall patent coverage for COL-003. We are continuing to focus on filing new patent applications that support COL-003 and the DETERx technology in both the U.S. and internationally,” said Michael Heffernan, CEO of Collegium.
Date: February 12, 2013
Source: Collegium Pharmaceutical Inc.